Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MT-CO2 | P00403 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | APP | P05067 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL21808210 | 0.95 | PTGS1 (0.47) | MT-CO2PTGS2PTGS1MAOBAPP | |
| SCHEMBL24875457 | 0.87 | MT-CO2 (0.47) | MT-CO2PTGS2PTGS1MAOBAPP | |
| SCHEMBL30192791 | 0.87 | MT-CO2 (0.47) | MT-CO2PTGS2PTGS1MAOBAPP | |
| SCHEMBL8476208 | 0.87 | MT-CO2 (0.47) | MT-CO2PTGS2PTGS1MAOBAPP | |
| SCHEMBL31560842 | 0.85 | PTGS1 (0.50) | MT-CO2PTGS2PTGS1MAOBAPP | |
| SCHEMBL11216724 | 0.82 | ALDH1A1 (0.58) | MT-CO2PTGS2PTGS1MAOBNPC1 | |
| SCHEMBL31430560 | 0.82 | ALDH1A1 (0.58) | MT-CO2PTGS2PTGS1MAOBNPC1 | |
| SCHEMBL732665 | 0.81 | AKR1C3 (0.55) | PTGS2PTGS1APPMAPTHPGD | |
| SCHEMBL14797664 | 0.81 | MT-CO2 (0.47) | MT-CO2PTGS2PTGS1MAOBAPP | |
| SCHEMBL7241661 | 0.81 | ALDH1A1 (0.51) | MT-CO2PTGS2PTGS1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3854781-B1 | DP ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2024-05-22 | — | — | EP | disclosed |
| US-20220204468-A1 | DP ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| US-11319296-B2 | DP antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-05-03 | — | — | US | disclosed |
| US-20220033371-A1 | DP ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| EP-3854781-A1 | DP ANTAGONIST | ONO Pharmaceutical Co., Ltd. (JP) | 2021-07-28 | — | — | EP | disclosed |
| CN-112739680-A | DP antagonists | 小野药品工业株式会社 | 2021-04-30 | — | — | CN | disclosed |
| EP-2760836-A1 | AMINE SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2014-08-06 | — | — | EP | disclosed |
| CN-103917523-A | Amine-substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH | 2014-07-09 | — | — | CN | disclosed |
| US-8765733-B2 | Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765733-B2 | Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765733-B2 | Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| WO-2013045451-A1 | AMINE SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013045451-A1 | AMINE SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079320-A1 | Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| US-20130079320-A1 | Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| US-20130079320-A1 | Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033371-A1 | DP ANTAGONIST | OPRL1, CNR1, NPSR1 | MT-CO2 4398/4885PTGS2 519/4885PTGS1 426/4885 |
| US-20130079320-A1 | Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | TRPV1, TRPA1, TRPV3 | MT-CO2 2413/4885PTGS2 629/4885PTGS1 536/4885 |
| US-20220204468-A1 | DP ANTAGONIST | OPRL1, CNR1, NPSR1 | MT-CO2 4398/4885PTGS2 519/4885PTGS1 426/4885 |
| US-11319296-B2 | DP antagonist | OPRL1, CNR1, NPSR1 | MT-CO2 4398/4885PTGS2 519/4885PTGS1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.